Literature DB >> 6357436

Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.

Z A Arlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6357436

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  11 in total

1.  Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: a potentiating role for amsacrine.

Authors:  L T Vlasveld; F E Zwaan; W E Fibbe; R T Tjon; T A Tham; P M Kluin; R Willemze
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma.

Authors:  Dadi Jiang; Arvin B Tam; Muthuraman Alagappan; Michael P Hay; Aparna Gupta; Margaret M Kozak; David E Solow-Cordero; Pek Y Lum; Nicholas C Denko; Amato J Giaccia; Quynh-Thu Le; Maho Niwa; Albert C Koong
Journal:  Mol Cancer Ther       Date:  2016-06-15       Impact factor: 6.261

3.  Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.

Authors:  R Liang; T K Chan; D Todd
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.

Authors:  J W Paxton; D Young; S M Evans; P Kestell; I G Robertson; E M Cornford
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.

Authors:  E M Cornford; D Young; J W Paxton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma.

Authors:  Ying Yi Chen; Graeme J Finlay; James A Kirker; Elaine S Marshall; Emma Richardson; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2010-08-10       Impact factor: 3.850

7.  The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.

Authors:  J W Paxton; P C Evans; J R Hardy
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans.

Authors:  J W Paxton; D Young; I G Robertson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.

Authors:  Z Arlin; R Mehta; E Feldman; P Sullivan; A Pucillo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.

Authors:  J W Paxton; J R Hardy; P C Evans; V J Harvey; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.